Morepen Laboratories Share Price Gains 20.00% After Q1 FY27 Results on 4 August 2026
- August 5, 2026
- Posted by: Kunal Singla
- Category: News
Morepen Laboratories share price Rs 69.18 on 4 Aug 2026. Up 20.00%. Q1 FY27 PAT Rs 56 Cr (+393.98% YoY). Rev Rs 570 Cr (+34.07% YoY).
The Morepen Laboratories share price gained 20.00% to Rs 69.18 on 4 August 2026 as the company reported Q1 FY27 results, with revenue grew +34.07% year on year to Rs 570 Cr from Rs 425 Cr in Q1 FY26 and net profit expanded +393.98% year on year to Rs 56 Cr from Rs 11 Cr in Q1 FY26. Investors tracking the Morepen Laboratories share price reacted to a quarterly report that delivered Rs 570 Cr in consolidated revenue and Rs 56 Cr in net profit for the quarter ended 30 June 2026. The Morepen Laboratories share price movement on results day is one of the first data points investors use to gauge market sentiment around the company Q1 FY27 performance, even before studying the underlying financials in detail.
Click Here – Get Free Investment Predictions
Morepen Laboratories Q1 FY27 Results at a Glance
The table below summarises the key Q1 FY27 metrics that drove the Morepen Laboratories share price reaction on 4 August 2026.
| Metric | Q1 FY27 (Jun 2026) | Q1 FY26 (Jun 2025) | YoY Change |
|---|---|---|---|
| Morepen Laboratories | Q1 FY27 Results on 4 August 2026 | ||
| Revenue | Rs 570 Cr | Rs 425 Cr | +34.07% |
| Net Profit (PAT) | Rs 56 Cr | Rs 11 Cr | +393.98% |
| Gross Margin | 13.0% | ||
| Share Price on 4 Aug 2026 | Rs 69.18 | N/A | +20.00% on 4 Aug |
Morepen Laboratories Share Price Reaction to Q1 FY27 Results
The Morepen Laboratories share price move of +20.00% to Rs 69.18 on 4 August 2026 is the market first verdict on the Q1 FY27 numbers. Share price moves on results days are driven by whether the actual figures beat or missed analyst expectations ahead of the announcement. The Morepen Laboratories share price reaction should be read alongside the underlying financials: revenue of Rs 570 Cr (+34.07% YoY) and PAT of Rs 56 Cr (+393.98% YoY) are the two metrics that will drive analyst estimate revisions for FY27.
Post-result volatility in the Morepen Laboratories share price is normal and typically settles over the following sessions as institutional investors complete their position adjustments. Investors who hold the Morepen Laboratories share price through earnings should focus on the fundamental trend rather than the single-day price move, which can be amplified by event-driven traders unwinding pre-result positions.
Screen Morepen Laboratories and Peers on the Univest Screener
Key Business Factors Behind the Morepen Laboratories Share Price Move
Revenue Performance in Q1 FY27
Morepen Laboratories reported revenue of Rs 570 Cr for Q1 FY27, grew +34.07% year on year from Rs 425 Cr in Q1 FY26. Revenue trajectory is the starting point for understanding why the Morepen Laboratories share price moved the way it did on 4 August 2026. Investors tracking the Morepen Laboratories share price should monitor whether this revenue growth rate sustains into Q2 FY27 (September quarter) or represents a seasonal or one-off dynamic that may not repeat.
Profitability and Margin Trends
The PAT of Morepen Laboratories for Q1 FY27 improved to Rs 56 Cr from Rs 11 Cr in Q1 FY26, a change of +393.98% year on year. The gross margin stood at 13.0% for the quarter. Profitability trends are a key driver of the Morepen Laboratories share price over the medium term, as consistent earnings improvement is what typically drives institutional accumulation of a stock. Investors holding the Morepen Laboratories share price should track whether this profit trajectory is sustainable into Q2 and Q3 FY27.
What Investors Should Watch in the Morepen Laboratories Share Price
Beyond the Q1 FY27 results, several factors will influence the Morepen Laboratories share price trajectory in the coming months. Management commentary on the Q2 FY27 outlook, particularly on demand trends, input cost movements, and any guidance upgrades or downgrades, will be closely watched. The Morepen Laboratories share price is also subject to broader market conditions including RBI monetary policy, FII activity, and sector-level sentiment.
For investors evaluating the Morepen Laboratories share price at current levels of Rs 69.18, the Q1 FY27 results provide a baseline. The sustainability of the revenue run rate at Rs 570 Cr per quarter and the profit level at Rs 56 Cr will determine whether the Morepen Laboratories share price re-rates higher or faces consolidation in subsequent sessions.
Download the Univest iOS App or Univest Android App to track the Morepen Laboratories share price and access Q1 FY27 results analysis.
Conclusion
The Morepen Laboratories share price gained 20.00% to Rs 69.18 on 4 August 2026 after the company reported Q1 FY27 results showing revenue of Rs 570 Cr (+34.07% YoY) and PAT of Rs 56 Cr (+393.98% YoY). The Morepen Laboratories share price reaction reflects the market initial assessment of the Q1 FY27 print. Investors should track Q2 FY27 results (due around October 2026) and management guidance for a more complete picture of the FY27 earnings trajectory before making significant decisions based on the The company at current levels.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What happened to the The stock after Q1 FY27 results?
Ans. The The shares gained 20.00% to Rs 69.18 on 4 August 2026, reacting to Q1 FY27 results that showed revenue of Rs 570 Cr and PAT of Rs 56 Cr.
What were the Morepen Laboratories Q1 FY27 results?
Ans. Morepen Laboratories reported revenue of Rs 570 Cr (+34.07% YoY) and PAT of Rs 56 Cr (+393.98% YoY) for Q1 FY27 (April to June 2026 quarter) announced on 4 August 2026.
What is the The scrip today?
Ans. The The counter was Rs 69.18 on 4 August 2026, the day Q1 FY27 results were announced. For the latest The company, check NSE (nseindia.com) or the Univest app.
Is Morepen Laboratories a good buy after Q1 FY27 results?
Ans. Any decision to buy The stock should be based on your own research and risk profile. Q1 FY27 results show PAT of Rs 56 Cr and revenue of Rs 570 Cr. Consult a SEBI-registered advisor before investing.
What is the PAT of Morepen Laboratories for Q1 FY27?
Ans. The PAT (net profit) of Morepen Laboratories for Q1 FY27 was Rs 56 Cr, a change of +393.98% year on year from Rs 11 Cr in Q1 FY26.
Where can I track the The shares?
Ans. The The scrip can be tracked on NSE (nseindia.com), BSE (bseindia.com), and the Univest app and screener for live prices, Q1 FY27 results analysis, and investor research.
